Viking Therapeutics' Weight-Loss Tablet Shows 3.3% Reduction in Early Clinical Study

Tuesday, 26 March 2024, 13:23

Viking Therapeutics' experimental weight-loss tablet, VK2735, demonstrated a significant reduction in weight by 3.3% in a small early-stage trial. This positive outcome met the expectations of Wall Street, leading to a 15% increase in the company's shares in premarket trading. The study revealed promising results for the oral version of the drug, offering a convenient option for patients seeking effective weight-loss solutions.
https://store.livarava.com/2fb316e7-eb94-11ee-aec1-63fd8ea994ba.jpg
Viking Therapeutics' Weight-Loss Tablet Shows 3.3% Reduction in Early Clinical Study

Viking Therapeutics Weight-Loss Tablet Study Results

Viking Therapeutics conducted an early-stage trial where volunteers experienced weight reduction using the experimental tablet, VK2735. The highest 40-milligram dose showed a notable weight loss of 3.3% compared to the placebo group after 28 days.

Market Trends in Weight-Loss Drugs

  • Leading companies like Eli Lilly and Novo Nordisk are exploring oral versions of weight-loss medications to provide patients with more convenient treatment options.
  • Viking Therapeutics' positive trial results indicate a potential shift towards effective oral weight-loss solutions in the market.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe